Evaluation of Two HIV Rapid Diagnostic Tests in a Context of Strains' Genetic Diversity in Mali

Josue Togo, Almoustapha Issiaka Maiga*, Mariam Sylla, Bourahima Kone, Oumar Dolo, Fatoumata Tata Traore, Samba Adama Sangare, Mamoudou Maiga, Souleymane Diallo, Robert Leo Murphy, Vincent Calvez, Anne Genevieve Marcelin

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

The rapid diagnostic tests used in most resource-limited countries offer little specificity in the differentiation of HIV-1, HIV-2, and HIV-1 + 2. World Health Organization (WHO) does periodically evaluate rapid tests in use in the South Countries. Despite the prequalification from WHO, it is necessary at local level to conduct comparative studies between the available tests. To do this in Mali, we conducted a cross-sectional study at the University Teaching Hospital Gabriel Touré and the Research and Training Center (SEREFO) of Bamako on 172 samples from retrospective and prospective studies. The goal of this project was to compare the following rapid tests: "HIV TRI-DOT" and OnSite HIV1/2 Ab Plus Combo Rapid Test for screening HIV-1 and HIV-2 to "ImmunoComb II BiSpot" (gold standard). The sensibility and specificity of "HIV TRI-DOT" for HIV-1 detection were 100% each [95% confidence interval (CI): 87.13-100 and 95.31-100]. Its performance for HIV-2 detection was 95.24% (95% CI: 84.21-98.68) (sensibility) and 100% (95% CI: 72.25-100) (specificity). The positive and negative predictive values were, respectively, 100% (95% CI: 91.24-100) and 83.33% (95% CI: 55.20-95.30). The sensibility and specificity of OnSite HIV1/2 Ab Plus Combo Rapid Test assay performance were 100% (95% CI: 87.13-100 and 95.31-100). Overall, OnSite HIV Ab Combo Rapid Test proved to be a good test for warm countries and does not require refrigeration in these settings. Blood and its products can be used to perform the test, unlike "ImmunoComb II BiSpot" and "HIV TRI-DOT," which must be kept cold and cannot be done with whole blood.

Original languageEnglish (US)
Pages (from-to)145-149
Number of pages5
JournalAIDS research and human retroviruses
Volume35
Issue number2
DOIs
StatePublished - Feb 1 2019

Fingerprint

Mali
Routine Diagnostic Tests
HIV-2
HIV
Confidence Intervals
HIV-1
Refrigeration
Teaching Hospitals
Retrospective Studies
Cross-Sectional Studies
Prospective Studies
Research

Keywords

  • HIV
  • Mali
  • West Africa
  • rapid diagnostic test

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Infectious Diseases

Cite this

Togo, J., Maiga, A. I., Sylla, M., Kone, B., Dolo, O., Traore, F. T., ... Marcelin, A. G. (2019). Evaluation of Two HIV Rapid Diagnostic Tests in a Context of Strains' Genetic Diversity in Mali. AIDS research and human retroviruses, 35(2), 145-149. https://doi.org/10.1089/aid.2017.0296
Togo, Josue ; Maiga, Almoustapha Issiaka ; Sylla, Mariam ; Kone, Bourahima ; Dolo, Oumar ; Traore, Fatoumata Tata ; Sangare, Samba Adama ; Maiga, Mamoudou ; Diallo, Souleymane ; Murphy, Robert Leo ; Calvez, Vincent ; Marcelin, Anne Genevieve. / Evaluation of Two HIV Rapid Diagnostic Tests in a Context of Strains' Genetic Diversity in Mali. In: AIDS research and human retroviruses. 2019 ; Vol. 35, No. 2. pp. 145-149.
@article{9200d4d655da4c7cadf72c2912c1850a,
title = "Evaluation of Two HIV Rapid Diagnostic Tests in a Context of Strains' Genetic Diversity in Mali",
abstract = "The rapid diagnostic tests used in most resource-limited countries offer little specificity in the differentiation of HIV-1, HIV-2, and HIV-1 + 2. World Health Organization (WHO) does periodically evaluate rapid tests in use in the South Countries. Despite the prequalification from WHO, it is necessary at local level to conduct comparative studies between the available tests. To do this in Mali, we conducted a cross-sectional study at the University Teaching Hospital Gabriel Tour{\'e} and the Research and Training Center (SEREFO) of Bamako on 172 samples from retrospective and prospective studies. The goal of this project was to compare the following rapid tests: {"}HIV TRI-DOT{"} and OnSite HIV1/2 Ab Plus Combo Rapid Test for screening HIV-1 and HIV-2 to {"}ImmunoComb II BiSpot{"} (gold standard). The sensibility and specificity of {"}HIV TRI-DOT{"} for HIV-1 detection were 100{\%} each [95{\%} confidence interval (CI): 87.13-100 and 95.31-100]. Its performance for HIV-2 detection was 95.24{\%} (95{\%} CI: 84.21-98.68) (sensibility) and 100{\%} (95{\%} CI: 72.25-100) (specificity). The positive and negative predictive values were, respectively, 100{\%} (95{\%} CI: 91.24-100) and 83.33{\%} (95{\%} CI: 55.20-95.30). The sensibility and specificity of OnSite HIV1/2 Ab Plus Combo Rapid Test assay performance were 100{\%} (95{\%} CI: 87.13-100 and 95.31-100). Overall, OnSite HIV Ab Combo Rapid Test proved to be a good test for warm countries and does not require refrigeration in these settings. Blood and its products can be used to perform the test, unlike {"}ImmunoComb II BiSpot{"} and {"}HIV TRI-DOT,{"} which must be kept cold and cannot be done with whole blood.",
keywords = "HIV, Mali, West Africa, rapid diagnostic test",
author = "Josue Togo and Maiga, {Almoustapha Issiaka} and Mariam Sylla and Bourahima Kone and Oumar Dolo and Traore, {Fatoumata Tata} and Sangare, {Samba Adama} and Mamoudou Maiga and Souleymane Diallo and Murphy, {Robert Leo} and Vincent Calvez and Marcelin, {Anne Genevieve}",
year = "2019",
month = "2",
day = "1",
doi = "10.1089/aid.2017.0296",
language = "English (US)",
volume = "35",
pages = "145--149",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

Togo, J, Maiga, AI, Sylla, M, Kone, B, Dolo, O, Traore, FT, Sangare, SA, Maiga, M, Diallo, S, Murphy, RL, Calvez, V & Marcelin, AG 2019, 'Evaluation of Two HIV Rapid Diagnostic Tests in a Context of Strains' Genetic Diversity in Mali', AIDS research and human retroviruses, vol. 35, no. 2, pp. 145-149. https://doi.org/10.1089/aid.2017.0296

Evaluation of Two HIV Rapid Diagnostic Tests in a Context of Strains' Genetic Diversity in Mali. / Togo, Josue; Maiga, Almoustapha Issiaka; Sylla, Mariam; Kone, Bourahima; Dolo, Oumar; Traore, Fatoumata Tata; Sangare, Samba Adama; Maiga, Mamoudou; Diallo, Souleymane; Murphy, Robert Leo; Calvez, Vincent; Marcelin, Anne Genevieve.

In: AIDS research and human retroviruses, Vol. 35, No. 2, 01.02.2019, p. 145-149.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Evaluation of Two HIV Rapid Diagnostic Tests in a Context of Strains' Genetic Diversity in Mali

AU - Togo, Josue

AU - Maiga, Almoustapha Issiaka

AU - Sylla, Mariam

AU - Kone, Bourahima

AU - Dolo, Oumar

AU - Traore, Fatoumata Tata

AU - Sangare, Samba Adama

AU - Maiga, Mamoudou

AU - Diallo, Souleymane

AU - Murphy, Robert Leo

AU - Calvez, Vincent

AU - Marcelin, Anne Genevieve

PY - 2019/2/1

Y1 - 2019/2/1

N2 - The rapid diagnostic tests used in most resource-limited countries offer little specificity in the differentiation of HIV-1, HIV-2, and HIV-1 + 2. World Health Organization (WHO) does periodically evaluate rapid tests in use in the South Countries. Despite the prequalification from WHO, it is necessary at local level to conduct comparative studies between the available tests. To do this in Mali, we conducted a cross-sectional study at the University Teaching Hospital Gabriel Touré and the Research and Training Center (SEREFO) of Bamako on 172 samples from retrospective and prospective studies. The goal of this project was to compare the following rapid tests: "HIV TRI-DOT" and OnSite HIV1/2 Ab Plus Combo Rapid Test for screening HIV-1 and HIV-2 to "ImmunoComb II BiSpot" (gold standard). The sensibility and specificity of "HIV TRI-DOT" for HIV-1 detection were 100% each [95% confidence interval (CI): 87.13-100 and 95.31-100]. Its performance for HIV-2 detection was 95.24% (95% CI: 84.21-98.68) (sensibility) and 100% (95% CI: 72.25-100) (specificity). The positive and negative predictive values were, respectively, 100% (95% CI: 91.24-100) and 83.33% (95% CI: 55.20-95.30). The sensibility and specificity of OnSite HIV1/2 Ab Plus Combo Rapid Test assay performance were 100% (95% CI: 87.13-100 and 95.31-100). Overall, OnSite HIV Ab Combo Rapid Test proved to be a good test for warm countries and does not require refrigeration in these settings. Blood and its products can be used to perform the test, unlike "ImmunoComb II BiSpot" and "HIV TRI-DOT," which must be kept cold and cannot be done with whole blood.

AB - The rapid diagnostic tests used in most resource-limited countries offer little specificity in the differentiation of HIV-1, HIV-2, and HIV-1 + 2. World Health Organization (WHO) does periodically evaluate rapid tests in use in the South Countries. Despite the prequalification from WHO, it is necessary at local level to conduct comparative studies between the available tests. To do this in Mali, we conducted a cross-sectional study at the University Teaching Hospital Gabriel Touré and the Research and Training Center (SEREFO) of Bamako on 172 samples from retrospective and prospective studies. The goal of this project was to compare the following rapid tests: "HIV TRI-DOT" and OnSite HIV1/2 Ab Plus Combo Rapid Test for screening HIV-1 and HIV-2 to "ImmunoComb II BiSpot" (gold standard). The sensibility and specificity of "HIV TRI-DOT" for HIV-1 detection were 100% each [95% confidence interval (CI): 87.13-100 and 95.31-100]. Its performance for HIV-2 detection was 95.24% (95% CI: 84.21-98.68) (sensibility) and 100% (95% CI: 72.25-100) (specificity). The positive and negative predictive values were, respectively, 100% (95% CI: 91.24-100) and 83.33% (95% CI: 55.20-95.30). The sensibility and specificity of OnSite HIV1/2 Ab Plus Combo Rapid Test assay performance were 100% (95% CI: 87.13-100 and 95.31-100). Overall, OnSite HIV Ab Combo Rapid Test proved to be a good test for warm countries and does not require refrigeration in these settings. Blood and its products can be used to perform the test, unlike "ImmunoComb II BiSpot" and "HIV TRI-DOT," which must be kept cold and cannot be done with whole blood.

KW - HIV

KW - Mali

KW - West Africa

KW - rapid diagnostic test

UR - http://www.scopus.com/inward/record.url?scp=85060945562&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060945562&partnerID=8YFLogxK

U2 - 10.1089/aid.2017.0296

DO - 10.1089/aid.2017.0296

M3 - Article

VL - 35

SP - 145

EP - 149

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 2

ER -